UCB’s Post

Get to know Lauren Unsworth, Research Associate II, Gene Editing. Lauren characterizes MaxCyte with one word—passion. “Passion is one of the big words to describe MaxCyte because everybody here is passionate about their job. We are passionate about our company, about our instrument.” With the help of our innovative technology, Lauren has been able to tap into her curiosity, explore new therapies, work with various cell types, and expand her knowledge, all to better serve our customers. Learn more about life at MaxCyte: www.maxcyte.com/careers

Excited to launch our latest talent playbook for Cell & Gene Therapy 💙   CGT offers enormous potential to extend and better the lives of patients globally, and there is a huge demand for talent to make this a reality.   Over $15B has been invested in CGT in the USA so far, with over 50% of this development happening across the East Coast.   Our Boston based team@ Bond Global has pulled together data and insights from across the biotech ecosystem to build your scale strategy for next year 🚀   - Understand the VC landscape. - Benchmark your EVP to attract the right talent. - Discover trends that could affect your hiring and people plans.   Download your copy: https://lnkd.in/gCBEzDwN   Christina (Smith) Harris   #BondBook #BondGlobal #Biotech #Insights

💡In the ever-evolving landscape of the life sciences industry, challenges abound, from labor shortages to #regulatory shifts and funding constraints. While these headwinds may seem daunting, particularly for research-stage companies in the cell and gene therapy (CGT) sector, there's reason for #optimism. ➡ Despite facing uncertainties, CGT firms possess unique strengths that position them well to weather these storms. Let's delve into the #macroeconomic landscape, explore its impact on CGT enterprises, and uncover the distinctive #opportunities that lie ahead for these #innovative players. 🌱 #LifeSciences #CellTherapy #GeneTherapy #Economy #Innovation #SymmetricTraining

📲Calling all the last minute registrants! We have over 💯+ attendees and 20+ industry speakers/panelists. Don't miss out! #FOMO #cellandgenetherapy #sanfrancisco #bayarea #SSF #genetherapy #biotechnology #scienceandtechnology #science #research #processdevelopment #largemolecule

Creating a closed-process, semi-automated workflow for human #MSCexpansion, harvest, and final fill While commercially available #bioreactor platforms allow for large-scale production of #celltherapies, they are often limited in scaling processes, are inherently inefficient, require skilled personnel, and lack flexibility. Next Thursday, join Entegris Inc.’s Julien Muzard (Field Applications Technologist) and Donnie Beers (LS Applications Leader, Cell and Gene therapy) as they demonstrate the use of off-the-shelf consumables in a closed semi-automated modular workflow as an alternative, more cost-effective approach compared to "all-in-one" systems. Attend to learn about: • Limitations in using commercially available #bioreactor platforms in the development and production of cell and #genetherapies • The creation and use of semi-automated modular workflows • When to deploy off-the-shelf consumables Register for this #webinar below:

Wow. The OmniaBio build blew my mind. There’s a couple things you should know: 1. Fifteen massive clean rooms - Designed specifically for cell and gene therapy manufacturing. - Ballroom style, meaning they are highly adaptable to nearly any process. 2. 120,000+ sq. ft. of total space - Not just space for clean rooms - But capacity for comprehensive services like QC, MSAT, packaging and training. 3. Less than 40 miles from the United States - Established international trade partnerships. - Seamless and rapid access to key US clinical sites. If you’re making a cell therapy… You need to come see this for yourself. #innovation #biotechnology #celltherapy

🚀 Discover the Power of Strong Branding in the CGT Industry! In the rapidly evolving world of Cell and Gene Therapy (CGT), standing out can be a challenge. Our latest blog post explores how good branding can demystify complex scientific concepts, instill confidence in partners and regulators, and build trust within and outside the organization. Don’t miss out on these valuable insights—read the full blog post now and unlock the secrets to building a strong brand in the CGT industry. https://lnkd.in/ggb3Yea5 #OCBio, #OrangeCountyBio, #CGT, #CellandGeneTherapy, #CellTherapy, #GeneTherapy, #Consulting, #Marketing, #Branding, #Brand

*On this day* the 28th June 2012: The CRISPR gene editing method was published by Jennifer Doudna and Emmanuelle Charpentier (the method was invented May 25th, 2012). The pair later received the 2020 Nobel Prize in Chemistry. If you currently work on Clustered Regularly Interspaced Short Palindromic Repeats techniques or are looking for opportunities to do so, I'd love to speak to you! #CRISPR #GeneEditing #geneticscissors #nobelprize #changingthegame #BarringtonJames

The success of cell and gene therapy trials hinges on overcoming unique logistical hurdles—challenges that contract research organizations are well-equipped to handle. From managing cryogenic transport to optimizing time, our latest white paper illustrates how CROs work alongside specialty logistics companies to streamline operations. Stay ahead with industry expert insights; read now https://lnkd.in/db6j8Qc2 #Logistics #HealthcareInnovation

Capsida Biotherapeutics’ CFO Julie Hakim will be presenting at the upcoming 7th Annual Gene Therapy for Rare Disorder conference. She will be leading the GENE THERAPY DECISION MAKERS’ BOOTCAMP on Tuesday, March 26, from 2:40-4 pm ET.   Julie will be diving into the crucial topic of "Improving Biotech Financial Risk Management," shedding light on pivotal aspects that shape the industry’s financial landscape. The session will cover:   🔹 Developing a framework for allocating money 🔹 Spreading risk across an R&D/clinical pipeline 🔹 Weighing up whether to produce in-house or outsource 🔹 Finetuning the timing of key financial decisions   #GeneTherapy #RareDisorders #Biotech #FinancialManagement #Capsida #IndustryInsights #ConferencePresentation